BR112013026976A2 - alfa glucosidade ácida modificada com processamento acelerado - Google Patents

alfa glucosidade ácida modificada com processamento acelerado

Info

Publication number
BR112013026976A2
BR112013026976A2 BR112013026976A BR112013026976A BR112013026976A2 BR 112013026976 A2 BR112013026976 A2 BR 112013026976A2 BR 112013026976 A BR112013026976 A BR 112013026976A BR 112013026976 A BR112013026976 A BR 112013026976A BR 112013026976 A2 BR112013026976 A2 BR 112013026976A2
Authority
BR
Brazil
Prior art keywords
modified
glucosity
acid
acid alpha
alpha
Prior art date
Application number
BR112013026976A
Other languages
English (en)
Inventor
Kudo Mariko
J Moreland Rodney
M Canfield William
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013026976(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112013026976A2 publication Critical patent/BR112013026976A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

alfa glucosidade ácida modificada com processamento acelerado a presente invenção refere-se a um polipeptídeo de alfa glucosidase ácida humana modificada dotado de capacidade hidrofóbica aumentada em ou perto do sítio de processamento de 70 kda de n-terminal, assim como os métodos para a produção e o uso da alfa glucosidade ácida humana modificada no tratamento de distúrbios de armazenagem do glicogênio.
BR112013026976A 2011-04-22 2012-04-20 alfa glucosidade ácida modificada com processamento acelerado BR112013026976A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
PCT/US2012/034479 WO2012145644A1 (en) 2011-04-22 2012-04-20 Modified acid alpha glucosidase with accelerated processing

Publications (1)

Publication Number Publication Date
BR112013026976A2 true BR112013026976A2 (pt) 2019-09-24

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026976A BR112013026976A2 (pt) 2011-04-22 2012-04-20 alfa glucosidade ácida modificada com processamento acelerado

Country Status (23)

Country Link
US (1) US20140186326A1 (pt)
EP (1) EP2699676A1 (pt)
JP (2) JP2014513952A (pt)
KR (1) KR20140037082A (pt)
CN (1) CN103797115A (pt)
AU (1) AU2012245280A1 (pt)
BR (1) BR112013026976A2 (pt)
CA (1) CA2833371A1 (pt)
CL (1) CL2013003010A1 (pt)
CO (1) CO6811810A2 (pt)
CR (1) CR20130555A (pt)
EC (1) ECSP13013036A (pt)
GT (1) GT201300252A (pt)
IL (1) IL228871A0 (pt)
MA (1) MA35125B1 (pt)
MX (1) MX2013012345A (pt)
NI (1) NI201300110A (pt)
PE (1) PE20140617A1 (pt)
RU (1) RU2013151875A (pt)
SG (2) SG10201605874TA (pt)
TN (1) TN2013000427A1 (pt)
WO (1) WO2012145644A1 (pt)
ZA (1) ZA201307696B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
SI3201320T1 (sl) 2014-09-30 2024-02-29 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
WO2017079729A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
KR20230041833A (ko) 2015-12-30 2023-03-24 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR20220145918A (ko) 2016-03-30 2022-10-31 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
BR112019004785A2 (pt) 2016-09-12 2019-06-04 Genethon variantes de alfa-glicosidase ácida e usos das mesmas
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
MX2022005916A (es) * 2019-11-19 2022-08-04 Asklepios Biopharmaceutical Inc Virus adenoasociado terapeutico que comprende promotores especificos del higado para el tratamiento de la enfermedad de pompe y los trastornos liposomales.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP1137762B1 (en) 1998-12-07 2008-10-08 Genzyme Corporation Treatment of pompe's disease
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
DK2266968T3 (da) 2001-07-16 2013-04-08 Genzyme Corp Syntese af UDP-glucose: N-acylsphingosin-glucosyltransferase-hæmmere
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
CN101942443A (zh) 2003-06-24 2011-01-12 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP4212541A1 (en) 2008-12-16 2023-07-19 Genzyme Corporation Oligosaccharide-protein conjugates and their intermediates
US8466340B2 (en) * 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
WO2012145644A1 (en) 2012-10-26
SG194486A1 (en) 2013-12-30
RU2013151875A (ru) 2015-05-27
MX2013012345A (es) 2015-05-07
CA2833371A1 (en) 2012-10-26
KR20140037082A (ko) 2014-03-26
SG10201605874TA (en) 2016-09-29
JP2014513952A (ja) 2014-06-19
AU2012245280A1 (en) 2013-11-07
EP2699676A1 (en) 2014-02-26
TN2013000427A1 (en) 2015-03-30
CR20130555A (es) 2013-12-09
MA35125B1 (fr) 2014-05-02
ZA201307696B (en) 2014-07-30
CN103797115A (zh) 2014-05-14
ECSP13013036A (es) 2015-04-30
US20140186326A1 (en) 2014-07-03
PE20140617A1 (es) 2014-05-28
IL228871A0 (en) 2013-12-31
NI201300110A (es) 2014-02-28
CL2013003010A1 (es) 2014-03-07
GT201300252A (es) 2015-02-09
JP2017035091A (ja) 2017-02-16
CO6811810A2 (es) 2013-12-16

Similar Documents

Publication Publication Date Title
BR112013026976A2 (pt) alfa glucosidade ácida modificada com processamento acelerado
BR112017008696A2 (pt) métodos e composições para células exterminadoras naturais
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
WO2014089241A3 (en) Molecular profiling for cancer
EA201492055A1 (ru) ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
NZ700515A (en) Biophotonic compositions, kits and methods
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
PH12014501604A1 (en) Polypeptides binding to human complement c5
MY169328A (en) Compositions for the treatment of dry eye
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
MX359854B (es) Anticuerpos anti-cxcr3.
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
ZA201704903B (en) Modified dnase and uses thereof
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX2021002985A (es) Polipeptidos del factor vii de accion corta.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.